Cowen Inc.

GAAP total revenues were $410.6 million, down 45% year over year from $747.5 million. GAAP net income attributable to common stockholders was $33.4 million, or $1.05 per diluted share, down from $145.8 million, or $4.34 per diluted share, in the prior-year period. Non-GAAP economic income proceeds were $331.6 million, down 52% year over year. Investment banking proceeds were $98.7 million, down 66%; brokerage proceeds were $197.8 million, down 11%; management fees were $20.7 million, down 24%; incentive income was a loss of $13 million; and investment income was $23.6 million. The company said comp-to-proceeds was 56.5%, and for full-year 2022 it is targeting a compensation ratio between 56% and 57%, absent a continued and prolonged decline in capital markets activity. Economic operating income was $42.8 million, or $1.35 per common share, and return on common equity was 16.6%. Common book value per share rose to $37.49 from $36.57 at year-end, and common equity was $1.04 billion. On capital returns, Cowen repurchased $24.1 million of stock, or 798,000 shares, and maintained its $0.12 quarterly dividend. On interest expense, management said the new swap implies second-quarter 2022 interest expense of about $5 million to $6 million, rising to about $9 million per quarter in the third quarter and thereafter.

Jeffrey Solomon framed the quarter as proof that Cowen’s diversified model can perform even in a severe downturn, noting the hardest capital markets environment in over a decade and still pointing to solid banking and exceptional markets results. He stressed that acquisitions like Quarton, MHT and Portico are expanding advisory capabilities and reducing dependence on ECM, while also highlighting growth in digital assets, ESG, and middle-market sponsor coverage. His tone was confident and defensive on valuation, arguing that Cowen should be viewed on earnings and ROE rather than tangible book value.

Stephen Lasota focused on the hard numbers and capital deployment. He detailed total revenues of $410.6 million, GAAP EPS of $1.05, comp expense of $187.2 million, fixed non-comp expenses of $40.9 million, variable non-comp expenses of $52.9 million, and D&A of $7.2 million, while noting the $18 million unrealized gain on the interest rate swap and $23.6 million of investment income. He also said common equity was $1.04 billion, book value per share was $37.49, ROE was 16.6%, and buybacks totaled $24.1 million, equivalent to 56% of economic operating income; he reiterated the full-year comp ratio target of 56% to 57% and said share repurchases will remain opportunistic.

Analysts pressed on the banking pipeline, buyback capacity, and why the share count has not fallen more despite steady repurchases. Management said the backlog is skewed more toward M&A than equity offerings, follow-ons do not really sit in backlog, and deal timing is being managed cautiously, especially in biotech. On capital returns, Solomon said the company remains aggressive and will stay within its buyback guidance, but share count is influenced by convert-related accounting, acquisitions, and RSUs. Questions also covered digital assets, SPAC regulation, ESG, and GP continuation funds; management said digital is an infrastructure-led opportunity, SPAC business is becoming more regulated but still useful for client relationships, ESG is a broad cross-sector growth theme, and GP continuation / secondaries are on the strategic agenda, with acquisitions in that area under consideration.